Bevacizumab biosimilar - Allergan/Amgen

Next Previous
Drug Profile

Bevacizumab biosimilar - Allergan/Amgen

Alternative Names: ABP-215 (Mvasi); Bevacizumab-awwb; Mvasi

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen; Watson Pharmaceuticals
  • Developer Allergan; Amgen
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma
  • Registered Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 18 Jan 2018 Registered for Breast cancer (Combination therapy, Metastatic disease) in Iceland, Liechtenstein, Norway, European Union (IV)
  • 18 Jan 2018 Registered for Cervical cancer (Combination therapy, Metastatic disease, Recurrent) in Liechtenstein, Iceland, Norway, European Union (IV)
  • 18 Jan 2018 Registered for Colorectal cancer (Combination therapy, Metastatic disease) in Liechtenstein, Iceland, Norway, European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top